For its study, the firm analyzed chargemasters at 34 hospital systems. They were looking specifically at a handful of outpatient drugs.
The study found academic medical centers had the highest prices and markups for both brand-name and generic drugs. In one instance, New York City-based NewYork-Presbyterian marked up cancer drug Neulasta to $50,000, which is 12.5 times what Medicare charges. Other hospitals charge an average of $20,000.
Analysts also found that generic drugs often had larger markups than brand name drugs.
The study comes as patients, lawmakers and the Trump administration place heightened pressure on the industry to reduce costs.
NewYork-Presbyterian did not immediately respond to Becker’s Hospital Review’s request for comment.
The study was first reported by Axios.
More articles on pharmacy:
Better pharmacy access sought for rural Colorado residents
Following its rival, Sanofi and Regeneron slash price of cholesterol drug by 60%
Mount Carmel’s chief pharmacy officer out amid overprescribing scandal
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
